Guidelines for Treatment of Advanced Kidney Cancer

Updated Guidelines for Treatment of Advanced Kidney Cancer

The National Comprehensive Cancer Network, an alliance of 20 leading cancer centers, announced that it has updated its guidelines for the treatment of advanced kidney cancer. Two drugs that were recently approved by the U.S. Food and Drug Administration (FDA) have been added to the guidelines as treatment options for advanced kidney cancer.

The kidneys are each filled with tiny tubules that clean and filter the blood-the process that removes waste and makes urine. Renal cell cancer is a malignancy involving these tubules of the kidney.

Advanced renal cell carcinoma refers to cancer that has spread beyond the kidney to different places in the body. Treatment for advanced renal cell carcinoma includes four basic treatment options: surgery, radiation, chemotherapy, and biologic therapy. (Biologic therapy uses substances made by the body or made in a laboratory that are used to boost, or direct, the patient’s own immune system to fight the cancer). Stem cells transplantation is also being evaluated.

In addition, two new drugs were recently approved by the FDA for treatment of advanced renal cell carcinoma. They are Sutent® (sunitinib) and Nexavar® (sorafenib); both drugs target enzymes involved in tumor growth and tumor blood supply.

The National Comprehensive Cancer Network has added Sutent and Nexavar as treatment options for first- or second-line treatment of advanced kidney cancer.

Patients with advanced kidney cancer may wish to talk with their doctor about the revised guidelines and the risks and benefits of treatment with Sutent or Nexavar.

Reference: National Comprehensive Cancer Network. NCCN Announces Important Updates to Kidney Cancer Clinical Practice Guidelines. March 7, 2006. Available at (Accessed March 27, 2006).

Related News:

Sutent® Approved for Kidney Cancer (1/27/06)

Nexavar® Approved for Treatment of Advanced Kidney Cancer (12/21/05)

Copyright © 2018 CancerConnect. All Rights Reserved.

Comments